EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics

Jinwei Zhang iD

Marine Drugs · 2025

DOI: 10.3390/md23070283 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Marine Drugs, 2025. Verfasst von Jinwei Zhang. Beteiligte Einrichtung: Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Hatherly Laboratories, Streatham Campus, Universi…. Hauptthemen laut MEDLINE: Aquatic Organisms, Neoplasms, Metabolic Diseases, Kidney Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Royal Society UK, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A2-2), ilimaquinone, and Aplidin (plitidepsin). Key mechanisms include autophagy modulation, immune checkpoint inhibition, anti-inflammatory effects, and mitochondrial homeostasis. Novel findings reveal glycosides’ dual role in cytotoxicity and immunomodulation, ilimaquinone’s induction of the DNA damage response, and Aplidin’s disruption of protein synthesis via eEF1A2 binding. Pharmacokinetic challenges and structure–activity relationships are critically analyzed, emphasizing nanodelivery systems and synthetic analog development. This review bridges mechanistic insights with translational potential, offering a cohesive framework for future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aquatic OrganismsNeoplasmsMetabolic DiseasesKidney DiseasesAntineoplastic AgentsBiological ProductsHumansAnimalsStructure-Activity RelationshipDrug Development

Stichwörter der Autor:innen

PRISMAautophagycancer therapyimmune checkpoint inhibitorskinase inhibitorsmarine-derived compoundsmetabolic-associated fatty liver diseasepharmacokineticsrenal diseasestructure–activity relationship

Substanzen

Antineoplastic AgentsBiological Products

Autor:innen und Institutionen

  • Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Hatherly Laboratories, Streatham Campus, University of Exeter, Exeter EX4 4PS, UK.
  • State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China.

ORCID-Profile: Jinwei Zhang

Förderung

  • The Royal Society UK
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J. (2025). Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. Marine Drugs. https://doi.org/10.3390/md23070283

Vancouver

Zhang J. Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics. Marine Drugs. 2025. doi:10.3390/md23070283

BibTeX
@article{Zhang2025,
  author = {Zhang, Jinwei},
  title = {Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics},
  journal = {Marine Drugs},
  year = {2025},
  doi = {10.3390/md23070283}
}
Kostenlos starten →